Serial measurement of interleukin‐6 and risk of mortality in anticoagulated patients with atrial fibrillation: Insights from ARISTOTLE and RE‐LY trials
Authors:
Open Access
- 8 June 2020
- journal article
- research article
- Published by Elsevier in Journal of Thrombosis and Haemostasis
- Vol. 18 (9) , 2287-2295
Abstract
No abstract availableKeywords
Funding Information
- Bristol-Myers Squibb
- Pfizer
This publication has 24 references indexed in Scilit:
- Biomarkers of inflammation and risk of cardiovascular events in anticoagulated patients with atrial fibrillationHeart, 2016
- Interleukin-6 and C-reactive protein and risk for death and cardiovascular events in patients with atrial fibrillationAmerican Heart Journal, 2015
- Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trialsThe Lancet, 2014
- Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial FibrillationAnnals of Internal Medicine, 2007
- Independent prognostic value of elevated high-sensitivity C-reactive protein in chronic heart failureAmerican Heart Journal, 2004
- Relationship Between Interleukin 6 and Mortality in Patients With Unstable Coronary Artery DiseaseJAMA, 2001
- Markers of Myocardial Damage and Inflammation in Relation to Long-Term Mortality in Unstable Coronary Artery DiseaseNew England Journal of Medicine, 2000
- Impact of Atrial Fibrillation on the Risk of DeathCirculation, 1998
- Inflammation, Aspirin, and the Risk of Cardiovascular Disease in Apparently Healthy MenNew England Journal of Medicine, 1997
- Atrial fibrillation as an independent risk factor for stroke: the Framingham Study.Stroke, 1991